Bhvita Jani, research manager at Signify Research, explains the technology trends she is seeing in the radiology X-ray market. She includes insights on digital radiography (DR), computed radiography (CR) and how the prices of digital detectors dropping have increased adoption of DR systems.

Stereotactic body radiotherapy (SBRT) guided by MRI for localised prostate cancer resulted in fewer toxicities and an improvement in quality of life compared with CT guidance, according to the randomised phase III MIRAGE trial.

Given the long- and short-term harms of opioids, cardiac surgeons stressed that it is feasible to put strict limits around perioperative opioid use without giving up pain control and patient satisfaction.

Building on his ASNC 2022 meeting president-elect address, Al-Mallah’s article in the Journal of Nuclear Cardiology urges readers to embrace the “significant innovations” that nuclear cardiology has seen in the past decade.

Here is a list of some key trends in radiology technology from the editors of Health Imaging and Radiology Business that clinicians should be aware of heading into 2023.

A short course of perioperative chemotherapy for locally advanced esophageal/gastroesophageal junction (GEJ) cancer led to outcomes similar to those achieved with more intensive multimodal therapy, according to a randomised trial reported here.

The bivalent COVID-19 booster targeting BA.4/5 showed high levels of protection against COVID-19 hospitalisation in older adults, an observational cohort study out of Israel showed.

Two artificial intelligence (AI) programs, including ChatGPT, have passed the U.S. Medical Licensing Examination (USMLE), according to two recent papers.

Children with overweight or obesity appeared to have abnormalities in the brain that could affect executive functioning, an analysis of data from the Adolescent Brain Cognitive Development (ABCD) Study showed.

Excluding systematic biopsy in favour of MRI-targeted biopsy in men with elevated prostate-specific antigen (PSA) levels reduced the probability of detecting clinically insignificant cancers, but at the risk of missing some clinically significant cancers and delaying their diagnosis.